A Study Designed to Compare the Tolerability of an Increased Dose of Enteric-coated Mycophenolate Acid (MPA) in Renal Transplant Patients Whose Dose of Mycophenolate Mofetil (MMF) Was Reduced Due to Gastrointestinal Symptoms

Inclusion criteria: * Recipients of first or second cadaveric, living unrelated or living related kidney transplant. * Patients on a reduced daily dose (500mg to 1500mg) of MMF with existing but tolerable and controlled gastrointestinal symptoms. * Recipients who are at least 4 weeks post renal transplantation with stable renal function. Exclusion criteria: * Multi organ transplant or previous transplant with organ other than kidney * History of GI disorder prior to transplant * Evidence of GI disorder induced by infection, underlying medical condition, or con med other than MMF * Modification of GI med or MMF dose within one week * Evidence of graft rejection, treatment of acute rejection, unstable renal function within 1 week of (baseline) visit Other protocol-defined inclusion/exclusion criteria may apply